(Total Views: 410)
Posted On: 03/16/2019 4:03:35 PM
Post# of 72448
You are right Smokenhot
Problem with "off label" indications , it is harder and harder to get approved by FDA/EMA unless trial will do sub-group analysis after completion of the study and/or
study protocol will allow such patients to participate.
There is so many other reasons for development of OM ( rads alone , chemo alone , idiopathic ) and it would be shame not be able to use the drug in those situations .
My opinion only
Problem with "off label" indications , it is harder and harder to get approved by FDA/EMA unless trial will do sub-group analysis after completion of the study and/or
study protocol will allow such patients to participate.
There is so many other reasons for development of OM ( rads alone , chemo alone , idiopathic ) and it would be shame not be able to use the drug in those situations .
My opinion only
(0)
(0)
